Open AccessDapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
Author(s) -
Zhengyang Hao,
Yanzhou Zhang
Publication year - 2022
Publication title -
international journal of general medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.722
H-Index - 36
ISSN - 1178-7074
DOI - 10.2147/ijgm.s366943
Subject(s) - medicine , empagliflozin , dapagliflozin , ejection fraction , heart failure , retrospective cohort study , benzhydryl compounds , cardiology , intensive care medicine , diabetes mellitus , type 2 diabetes , endocrinology , chemistry , organic chemistry , bisphenol a , epoxy
Dapagliflozin 10 mg and empagliflozin 10 mg have been recommended to treat heart failure with reduced ejection fraction (HFrEF), and the purpose of this study was to compare the efficacy and safety of them in HFrEF.